CERUS CORP

Insider selling spikes at Cerus Corp reveal the CEO’s strategy amid a 121% year‑to‑date gain and a high‑risk biotech focus on pathogen‑inactivation technology.

Insider sale of Cerus Corp shares shows liquidity play, not confidence drop, amid strong FDA/EMA approvals, 95% contamination reduction, and $1,500/patient savings. 160 characters

Insider buying shows confidence in CERUS’s pathogen‑inactivation platform, with RSU purchases by top executives suggesting future upside despite current volatility.

Insightful insider‑trading analysis of Cerus Corp reveals routine COO sell‑orders, balanced by executive buys, amid strong pathogen‑inactivation pipeline and FDA Fast‑Track approvals—an essential read for investors tracking biotech growth.

Insightful review of Cerus Corp’s insider sales, clinical validation, FDA clearance and market outlook for its pathogen‑inactivation platelet system.

Insider buying at Cerus Corp signals leadership confidence amid market swings, spotlighting the company’s pathogen‑inactivation tech, growing reimbursement prospects, and potential upside for investors.